Terms: = Ovarian cancer AND P2RY8, RP11-261P4_4, 286530, ENSG00000182162, MGC50878, P2Y8, Q86VZ1 AND Clinical Outcome
236 results:
1. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
2. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract] [Full Text] [Related]
3. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
Konaté MM; Li MC; McShane LM; Zhao Y
Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
[TBL] [Abstract] [Full Text] [Related]
5. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in ovarian cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract] [Full Text] [Related]
6. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience.
Kim MS; Jeong SY; Lee YY; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
Taiwan J Obstet Gynecol; 2022 Mar; 61(2):333-338. PubMed ID: 35361397
[TBL] [Abstract] [Full Text] [Related]
8. CTLA-4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer.
Chen J; Kang S; Wu J; Zhao J; Si W; Sun H; Li Y
J Obstet Gynaecol Res; 2022 May; 48(5):1240-1247. PubMed ID: 35150042
[TBL] [Abstract] [Full Text] [Related]
9. Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant.
Zhang J; Zhang R; Ye Y
Bioengineered; 2021 Dec; 12(2):10541-10552. PubMed ID: 34709112
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract] [Full Text] [Related]
11. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Onder FC; Durdagi S; Kahraman N; Uslu TN; Kandemir H; Atici EB; Ozpolat B; Ay M
Bioorg Chem; 2021 Nov; 116():105296. PubMed ID: 34488125
[TBL] [Abstract] [Full Text] [Related]
12. Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer.
Lin Q; Liu W; Xu S; Sun L
Arch Gynecol Obstet; 2022 Mar; 305(3):683-691. PubMed ID: 34453586
[TBL] [Abstract] [Full Text] [Related]
13. A Way to Reduce the Occurrence of Intraoperative Capsule Rupture in Presumed clinically Early-stage ovarian cancer with Adhesions to the Abdominal Wall.
Li J; Duan J; Mao R; Jiang W
J Minim Invasive Gynecol; 2022 Jan; 29(1):16. PubMed ID: 34265440
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD).
Macchia G; Jereczek-Fossa BA; Lazzari R; Cerrotta A; Deodato F; Ippolito E; Aristei C; Gambacorta MA; Scambia G; Valentini V; Ferrandina G
Int J Gynecol Cancer; 2022 Jul; 32(7):939-943. PubMed ID: 34155084
[TBL] [Abstract] [Full Text] [Related]
15. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract] [Full Text] [Related]
16. Significance of ERCC1 and Hormonal Receptor Expression in ovarian cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract] [Full Text] [Related]
17. Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Iida Y; Okamoto A; Hollis RL; Gourley C; Herrington CS
Int J Gynecol Cancer; 2021 Apr; 31(4):605-616. PubMed ID: 32948640
[TBL] [Abstract] [Full Text] [Related]
18. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the Uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
19. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract] [Full Text] [Related]
20. Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
Jiang YX; Siu MK; Wang JJ; Mo XT; Leung TH; Chan DW; Cheung AN; Ngan HY; Chan KK
Br J Cancer; 2020 Jul; 123(2):275-287. PubMed ID: 32390009
[TBL] [Abstract] [Full Text] [Related]
[Next]